SLC16A3 and prostate carcinoma: It has been evaluated as an antitumor agent in patients with prostate cancer, stomach cancer, and diffuse large b-cell lymphoma in a Phase I clinical trials.[70–74] Since hypoxia-induced MCT4 is the major isoform in most highly aggressive tumor, scientists have been searching for MCT4-specific inhibitors.